The role of E2F2 in cancer progression and its value as a therapeutic target

被引:3
|
作者
Gao, Yang [1 ,2 ]
Qiao, Xinjie [3 ]
Liu, Zhenhui [1 ,2 ]
Zhang, Wenzhou [1 ,2 ]
机构
[1] Zhengzhou Univ, Dept Pharm, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Dept Rhinol, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
基金
中国国家自然科学基金;
关键词
cancer progression; therapeutic target; function; strategy; CELL-PROLIFERATION; GASTRIC-CANCER; PROMOTES PROLIFERATION; REGULATING E2F2; DOWN-REGULATION; POOR-PROGNOSIS; DNA-BINDING; TRANSCRIPTION; DP; INHIBITION;
D O I
10.3389/fimmu.2024.1397303
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The E2F family of transcription factors plays a crucial role in the regulation of cell cycle progression and cell proliferation. Accumulative evidence indicates that aberrant expression or activation of E2F2 is a common phenomenon in malignances. E2F2 has emerged as a key player in the development and progression of various types of tumors. A wealth of research has substantiated that E2F2 could contribute to the enhancement of tumor cell proliferation, angiogenesis, and invasiveness. Moreover, E2F2 exerts its influence on a myriad of cellular processes by engaging with a spectrum of auxiliary factors and downstream targets, including apoptosis and DNA repair. The dysregulation of E2F2 in the context of carcinogenesis may be attributable to a multitude of mechanisms, which encompass modifications in upstream regulatory elements or epigenetic alterations. This review explores the function of E2F2 in cancer progression and both established and emerging therapeutic strategies aiming at targeting this oncogenic pathway, while also providing a strong basis for further research on the biological function and clinical applications of E2F2.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] LBX2-AS1 promotes ovarian cancer progression by facilitating E2F2 gene expression via miR-455-5p and miR-491-5p sponging
    Cao, Jian
    Wang, Huan
    Liu, Guangquan
    Tang, Ranran
    Ding, Ye
    Xu, Pengfei
    Wang, Huayu
    Miao, Juan
    Gu, Xiaoyan
    Han, Suping
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (02) : 1178 - 1189
  • [42] miR-365 Suppresses Cholangiocarcinoma Cell Proliferation and Induces Apoptosis by Targeting E2F2
    Chen, Lunjian
    Huang, Xiaorong
    Chen, Xinxin
    ONCOLOGY RESEARCH, 2018, 26 (09) : 1375 - 1382
  • [43] Emerging role of E2F8 in human cancer
    Lee, Da Young
    Chun, Jung Nyeo
    Cho, Minsoo
    So, Insuk
    Jeon, Ju-Hong
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2023, 1869 (06):
  • [44] The E2F transcription factor 2: What do we know?
    Li, Luwen
    Wang, Shiguan
    Zhang, Yihang
    Pan, Jihong
    BIOSCIENCE TRENDS, 2021, 15 (02) : 83 - 92
  • [45] Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism
    Wang, Tong
    Wang, Zhiyong
    Niu, Ruifang
    Wang, Liang
    CANCER BIOLOGY & MEDICINE, 2019, 16 (04) : 671 - 687
  • [46] PPAR-γ Ligand Inhibits Nasopharyngeal Carcinoma Cell Proliferation and Metastasis by Regulating E2F2
    Yang, Ping-Li
    Wang, Jia-Shun
    Cheng, Xiao-Mei
    Chen, Jing-Cai
    Zhu, Hui
    Li, Xiao-Lan
    Cao, Li
    Tang, Wei
    PPAR RESEARCH, 2019, 2019
  • [47] RhoGDI2 as a therapeutic target in cancer
    Cho, Hee Jun
    Baek, Kyoung Eun
    Yoo, Jiyun
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (01) : 67 - 75
  • [48] The E2F family and the role of E2F1 in apoptosis
    Wu, Zhenlong
    Zheng, Shunsheng
    Yu, Qiang
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (12) : 2389 - 2397
  • [49] E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival
    Xie, L.
    Li, T.
    Yang, L. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (09) : 2150 - 2156
  • [50] MiR-544a Regulates Synovial Cell Proliferation, Invasion, Migration and Apoptosis by Targeting E2F2
    Pan, Lingxiao
    Gan, Kaifeng
    JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2019, 9 (08) : 1065 - 1072